Financial Wire

Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study

-- Nxera Pharma (TYO:4565) said its partner Neurocrine Biosciences has dosed the first patient in a mid-stage trial of an experimental schizophrenia treatment, triggering a $22.5 million milestone payment to the Japanese drugmaker, according to a Monday filing on the Tokyo Stock Exchange.

The Phase 2 study will evaluate NBI-1117570, an oral dual muscarinic M1/M4 receptor agonist discovered by Nxera, in adults with schizophrenia requiring in-patient care. The payment will be booked as revenue in the first quarter of fiscal 2026, Nxera said.

The randomized, double-blind, placebo-controlled trial is expected to enroll about 120 patients. Its main goal is to measure changes in the Positive and Negative Syndrome Scale (PANSS) total score, a standard tool used to assess symptom severity, while also tracking safety and tolerability.

NBI-1117570 targets muscarinic acetylcholine receptors in the brain, with M1 linked to cognitive function and M4 associated with psychosis. The compound was developed using Nxera's NxWave drug discovery platform and is being advanced under a multi-program partnership with Neurocrine.

Related Articles

Asia

HSBC Holdings to Redeem $2 Billion Debt

HSBC Holdings (HKG:0005) plans to redeem $2.00 billion in debt, according to a Hong Kong bourse filing Friday.The bank is looking to redeem its 1.589% fixed rate/floating rate senior unsecured notes due 2027.The notes will be redeemed on May 24, the bank said.

$HKG:0005
Asia

Market Chatter: Shin-Etsu's $3.4 Billion US Investment Strengthens PVC Supply Resilience Amid Iran War

Shin-Etsu Chemical's (TYO:4063) additional $3.4 billion investment in its U.S. polyvinyl chloride operation in March has helped it withstand supply shocks better than many rivals who are raising prices or cutting output amid the Middle East turmoil, Nikkei Asia reported on Friday.While price competition in commodity-grade PVC remains fierce and massive output increases from Chinese suppliers have pushed numerous competitors into losses or plant closures, Shin-Etsu leverages its U.S. geographical advantage, the publication said.Through its American subsidiary Shintech, the company produces PVC using ethylene derived from U.S. shale gas, which exposes it to less geopolitical risk than oil-derived feedstocks from the Middle East, and enables stable, inexpensive procurement, the news agency said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$TYO:4063
Asia

Southern Cross Gold Consolidated Says Directors Boost Shareholdings With Stock Options Exercise; Shares Down 4%

Southern Cross Gold Consolidated (ASX:SX2) said certain of its directors exercised stock options to acquire about 7.8 million of the company's shares, generating roughly AU$5.5 million of proceeds for Southern Cross, according to a Friday filing with the Australian bourse.Following the exercise, the directors together own about 12.6 million shares, or 4.7% of the company's issued shares on a non-diluted basis, representing a material increase in their direct beneficial shareholding, per the filing.The directors plan to keep their holdings for long-term investment purposes.Additionally, Springtide Capital, a company associated with Southern Cross shareholder Darren Morcombe, has exercised 1.5 million stock options at AU$1.20 per share.Meanwhile, Morcombe has acquired an additional 950,618 shares via on-market purchases, increasing his aggregate beneficial shareholding by about 2.5 million shares to bring his total ownership of Southern Cross to 31.4 million shares, the company said.Shares of Southern Cross were down nearly 4% in recent Friday trade.

$ASX:SX2